PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.12
D/E of 0.12 versus zero Biotechnology median. Walter Schloss would verify if our leverage provides competitive advantages.
0.76
Very conservative net debt at 50-90% of Biotechnology median of 0.98. Philip Fisher would suggest checking if this conservatism supports R&D and growth investments.
-7.24
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.25
Current ratio below 50% of Biotechnology median of 2.88. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.